These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31332938)

  • 1. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis.
    Crossan C; Majumdar A; Srivastava A; Thorburn D; Rosenberg W; Pinzani M; Longworth L; Tsochatzis EA
    Liver Int; 2019 Nov; 39(11):2052-2060. PubMed ID: 31332938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease.
    Srivastava A; Jong S; Gola A; Gailer R; Morgan S; Sennett K; Tanwar S; Pizzo E; O'Beirne J; Tsochatzis E; Parkes J; Rosenberg W
    BMC Gastroenterol; 2019 Jul; 19(1):122. PubMed ID: 31296161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
    J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
    Congly SE; Shaheen AA; Swain MG
    PLoS One; 2021; 16(5):e0251741. PubMed ID: 34019560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis.
    Asphaug L; Thiele M; Krag A; Melberg HO
    Hepatology; 2020 Jun; 71(6):2093-2104. PubMed ID: 31595545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
    Stevenson M; Lloyd-Jones M; Morgan MY; Wong R
    Health Technol Assess; 2012; 16(4):1-174. PubMed ID: 22333291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD.
    Pennisi G; Enea M; Pandolfo A; Celsa C; Antonucci M; Ciccioli C; Infantino G; La Mantia C; Parisi S; Tulone A; Di Marco V; Craxì A; Cammà C; Petta S
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1293-1302.e5. PubMed ID: 35842119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    Srivastava A; Gailer R; Tanwar S; Trembling P; Parkes J; Rodger A; Suri D; Thorburn D; Sennett K; Morgan S; Tsochatzis EA; Rosenberg W
    J Hepatol; 2019 Aug; 71(2):371-378. PubMed ID: 30965069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
    J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
    Thiele M; Madsen BS; Hansen JF; Detlefsen S; Antonsen S; Krag A
    Gastroenterology; 2018 Apr; 154(5):1369-1379. PubMed ID: 29317276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    Rhodes FA; Trembling P; Panovska-Griffiths J; Tanwar S; Westbrook RH; Rodger A; Rosenberg WM
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1435-1449. PubMed ID: 33171534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.
    Anstee QM; Lawitz EJ; Alkhouri N; Wong VW; Romero-Gomez M; Okanoue T; Trauner M; Kersey K; Li G; Han L; Jia C; Wang L; Chen G; Subramanian GM; Myers RP; Djedjos CS; Kohli A; Bzowej N; Younes Z; Sarin S; Shiffman ML; Harrison SA; Afdhal NH; Goodman Z; Younossi ZM
    Hepatology; 2019 Nov; 70(5):1521-1530. PubMed ID: 31271665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
    Schmid P; Bregenzer A; Huber M; Rauch A; Jochum W; Müllhaupt B; Vernazza P; Opravil M; Weber R;
    PLoS One; 2015; 10(9):e0138838. PubMed ID: 26418061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
    Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
    Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease?
    McPherson S; Dyson JK; Jopson L; Masson S; Patel P; Anstee QM
    Aliment Pharmacol Ther; 2024 Jul; 60(2):267-273. PubMed ID: 38860621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
    Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
    Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study.
    Majumdar A; Campos S; Gurusamy K; Pinzani M; Tsochatzis EA
    Hepatology; 2020 Feb; 71(2):627-642. PubMed ID: 31297832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
    Vilar-Gomez E; Lou Z; Kong N; Vuppalanchi R; Imperiale TF; Chalasani N
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2305-2314.e12. PubMed ID: 32289535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.